OTCMKTS:FSDDF FSD Pharma (FSDDF) Stock Price, News & Analysis $3.70 +0.09 (+2.49%) As of 09/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About FSD Pharma Stock (OTCMKTS:FSDDF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FSD Pharma alerts:Sign Up Key Stats Today's Range$3.60▼$3.9050-Day Range$2.84▼$3.8052-Week Range$3.43▼$68.66Volume193,807 shsAverage Volume11,100 shsMarket Capitalization$28.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview FSD Pharma Inc. is a Canadian biopharmaceutical company focused on developing therapies for neurodegenerative and inflammatory disorders. The company’s research activities have included treatments for multiple sclerosis and other conditions involving inflammation, myelin damage and nervous-system dysfunction. FSD Pharma’s pipeline has included Lucid-21-302, also known as Lucid-MS, an investigational small-molecule therapy designed to address mechanisms associated with multiple sclerosis, including demyelination and neuroprotection. The company has also developed FSD-201, an ultra-micronized formulation of palmitoylethanolamide being investigated for its potential anti-inflammatory properties. Founded in Canada, FSD Pharma initially operated with a focus on the medical cannabis sector before shifting its strategy toward pharmaceutical drug development. Its activities have included preclinical research and clinical development conducted through Canadian and U.S. regulatory frameworks. The company has been associated with co-founder Anthony Durkacz, who has served in senior leadership roles.AI Generated. May Contain Errors. Read More Receive FSDDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FSDDF Stock News HeadlinesFreya Pharma Solutions Strengthens Leadership with Appointment of Distinguished Supervisory BoardJanuary 28, 2025 | markets.businessinsider.comQNTM Quantum BioPharma Ltd.August 31, 2024 | seekingalpha.comHas Dylan Jovine lost his mind?SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation. But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly. An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151. | Behind the Markets (Ad)FSD Pharma Inc. (HUGE)May 17, 2024 | finance.yahoo.comFSD Pharma Inc. Obtains Final Order for Plan of ArrangementNovember 27, 2023 | benzinga.comFSD Pharma gets court complaint alleging breach of nondisclosure agreementMay 12, 2023 | msn.comFSD Pharma Inc Ordinary Shares - Class B (Sub Voting)March 31, 2023 | morningstar.comMFSD Pharma's Australian Entity To Proceed With Phase I Trial For Major Depressive DisorderMarch 23, 2023 | benzinga.comSee More Headlines FSDDF Stock Analysis - Frequently Asked Questions How have FSDDF shares performed this year? FSD Pharma's stock was trading at $7.33 at the beginning of the year. Since then, FSDDF stock has decreased by 49.5% and is now trading at $3.70. How do I buy shares of FSD Pharma? Shares of FSDDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:FSDDF Previous SymbolOTCMKTS:FSDDF CIKN/A Webwww.quantumbiopharma.com Phone(416) 854-8884FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.81 Quick Ratio1.60 Sales & Book Value Annual Sales$70 thousand Price / Sales400.66 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares7,580,000Free FloatN/AMarket Cap$28.05 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:FSDDF) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FSD Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FSD Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
